Voyager Therapeutics, Inc. (VYGR)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Voyager Therapeutics, Inc. (VYGR)
Go deeper and ask any question about VYGR
Company Performance
Current Price
as of Sep 13, 2024$6.25
P/E Ratio
21.82
Market Cap
$340.83M
Description
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Metrics
Overview
- HQLexington, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerVYGR
- Price$6.25+0.48%
Trading Information
- Market Cap$340.83M
- Float82.84%
- Average Daily Volume (1m)374,235
- Average Daily Volume (3m)433,160
- EPS$0.32
Company
- Revenue$143.77M
- Rev Growth (1yr)509.48%
- Net Income-$10.14M
- Gross Margin95.29%
- EBITDA Margin-46.09%
- EBITDA-$13.63M
- EV$132.50M
- EV/Revenue0.92
- P/E21.82
- P/S2.51
Documents
SEC Filings
Earnings Calls